Cho Sung-Min, Robba Chiara, Diringer Michael N, Hanley Daniel F, Hemphill J Claude, Horn Janneke, Lewis Ariane, Livesay Sarah L, Menon David, Sharshar Tarek, Stevens Robert D, Torner James, Vespa Paul M, Ziai Wendy C, Spann Marcus, Helbok Raimund, Suarez Jose I
Neuroscience Critical Care Division, Departments of Neurology, and Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, 600 N. Wolfe Street , Baltimore, MD, 21287, USA.
IRCCS for Oncology and Neuroscience and Department of Surgical Science and Integrated Diagnostic, San Martino Policlinico Hospital, University of Genoa, Genoa, Italy.
Neurocrit Care. 2024 Feb;40(1):74-80. doi: 10.1007/s12028-023-01813-2. Epub 2023 Aug 3.
Limited data exist regarding the optimal clinical trial design for studies involving persons with disorders of consciousness (DoC), and only a few therapies have been tested in high-quality clinical trials. To address this, the Curing Coma Campaign Clinical Trial Working Group performed a gap analysis on the current state of clinical trials in DoC to identify the optimal clinical design for studies involving persons with DoC.
The Curing Coma Campaign Clinical Trial Working Group was divided into three subgroups to (1) review clinical trials involving persons with DoC, (2) identify unique challenges in the design of clinical trials involving persons with DoC, and (3) recommend optimal clinical trial designs for DoC.
There were 3055 studies screened, and 66 were included in this review. Several knowledge gaps and unique challenges were identified. There is a lack of high-quality clinical trials, and most data regarding patients with DoC are based on observational studies focusing on patients with traumatic brain injury and cardiac arrest. There is a lack of a structured long-term outcome assessment with significant heterogeneity in the methodology, definitions of outcomes, and conduct of studies, especially for long-term follow-up. Another major barrier to conducting clinical trials is the lack of resources, especially in low-income countries. Based on the available data, we recommend incorporating trial designs that use master protocols, sequential multiple assessment randomized trials, and comparative effectiveness research. Adaptive platform trials using a multiarm, multistage approach offer substantial advantages and should make use of biomarkers to assess treatment responses to increase trial efficiency. Finally, sound infrastructure and international collaboration are essential to facilitate the conduct of trials in patients with DoC.
Conduct of trials in patients with DoC should make use of master protocols and adaptive design and establish international registries incorporating standardized assessment tools. This will allow the establishment of evidence-based practice recommendations and decrease variations in care.
关于意识障碍(DoC)患者研究的最佳临床试验设计,现有数据有限,且仅有少数疗法在高质量临床试验中得到检验。为解决这一问题,昏迷治疗运动临床试验工作组对DoC临床试验的现状进行了差距分析,以确定针对DoC患者研究的最佳临床设计。
昏迷治疗运动临床试验工作组分为三个子组,以(1)审查涉及DoC患者的临床试验,(2)确定涉及DoC患者的临床试验设计中的独特挑战,以及(3)推荐针对DoC的最佳临床试验设计。
共筛选出3055项研究,本综述纳入了66项。确定了几个知识空白和独特挑战。缺乏高质量的临床试验,且大多数关于DoC患者的数据基于针对创伤性脑损伤和心脏骤停患者的观察性研究。缺乏结构化的长期结局评估,在方法、结局定义和研究实施方面存在显著异质性,尤其是在长期随访方面。开展临床试验的另一个主要障碍是缺乏资源,尤其是在低收入国家。基于现有数据,我们建议采用使用主方案、序贯多重评估随机试验和比较有效性研究的试验设计。采用多臂、多阶段方法的适应性平台试验具有显著优势,应利用生物标志物来评估治疗反应以提高试验效率。最后,完善的基础设施和国际合作对于促进DoC患者的试验开展至关重要。
对DoC患者进行试验应采用主方案和适应性设计,并建立纳入标准化评估工具的国际登记处。这将有助于制定基于证据的实践建议并减少护理差异。